γ-Рецепторы, активируемые пролифераторами пероксисом, и артериальная гипертония (уроки истории исследований) - Журнал Терапевтический архив №9 Вопросы кардиологии 2013

γ-Рецепторы, активируемые пролифераторами пероксисом, и артериальная гипертония (уроки истории исследований)

Расин М.С. γ-Рецепторы, активируемые пролифераторами пероксисом, и артериальная гипертония (уроки истории исследований). Терапевтический архив (архив до 2018 г.). 2013;85(9):118-123.

Читать PDF

Аннотация

Проведен анализ данных о применении тиазолинодионов в клинике, генетических наблюдений у людей и экспериментов с удалением гена PPAR-γ, а также данных о роли α- и β-рецепторов, активируемых пролифераторами пероксисом (PPAR’s), в функции эндотелия сосудов, симпатического отдела вегетативной нервной системы и почечной реабсорбции натрия. Сделан вывод о том, что тоническая активность PPAR’s является универсальным защитным механизмом, противодействующим развитию артериальной гипертонии.

Ключевые слова: PPAR-γ, артериальная гипертония, тиазолинодионы.

________________________________________________

The paper analyzes data from the clinical use of thiazolidinediones, human genetic observations and experiments with peroxisome proliferator-activated receptor (PPAR-γ) gene removal, and also those on the role of PPAR-α and -β in the function of the vascular endothelium, sympathetic autonomic nervous system, and renal sodium reabsorption. It is concluded that the tonic activity of PPAR is a universal protective mechanism counteracting the development of hypertension.

Key words: peroxisome proliferator-activated receptors-γ, hypertension, thiazolidinediones.

Список литературы

Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Proc Natl Acad Sci USA 1999; 47: 645-650.
Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
Lehmann J.M., Moore L.B., Smith-Oliver T.A. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
Getz G.S. Bridging the innate and adaptive immune systems. J Lipid Res 2005; 46: 619-627.
Barroso I., Gurnell M., Crowley V.E.F. еt al. Dominant negative mutations in human PPAR are associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
Pascual G., Fong A. L., Ogawa S. et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Proc Natl Acad Sci USA 2005; 402: 880-883.
Gurnell M., David B., Savage Е. еt al. PPAR ligand resistance (PLR) syndrome. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor and Its Therapeutic Modulation. J Clin Endocrinol Metab 2003; 88: 2412-2421.
Fonseca V.A. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003; 18: 50J-60J.
Reaven G.M. Relationships Among Insulin Resistance, Type 2 Diabetes, Essential Hypertension, and Cardiovascular Disease: Similarities and Differences. J Clin Hypertens 2011; 13: 238-243.
Расин А.М., Кайдашев И.П., Расин М.С. Пероксисом пролифераторактивирующие рецепторы и их роль в системном воспалении, атерогенезе, артериальной гипертензии и хроническом обструктивном заболевании легких (обзор литературы). Український тер журн 2006; 2: 100-108.
Desvergne В., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18 (6): 1321-1332.
Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290: 3000-3002.
Agostini M., Gurnell M., Savage D.B. еt al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor. Endocrinology 2004; 145: 1527-1538.
Agarwal A.K., Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy J Clin Endocrinol Metab 2002; 87: 408-411.
Кайдашев И.П. NF-κB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Междунар эндокринол журн 2011; 3 (35): 35-40.
Кайдашев І.П., Расін О.М., Микитюк М.В., Расін М.С. Аторвастатин та розиглітазон індукують апоптоз моноцитів/макрофагів крові: роль поліморфізму гена PPARγ. Ліки 2007; 3-4: 55-61.
Stefanski A., Majkowska1L., Ciechanowicz A. еt al. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obeshe patients with type II diabetes. J Hum Hypertens 2006; 20; 684-692.
Potenza M.A., Gagliardi S., De Benedictis А. еt al. Endocrinol Metab 2009; 297: E685-E694.
Tsai Y.S., Kim H.J., Takahashi N. et al. J Clin Invest 2009; 114: 240-249.
Beyer A.M. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 2008; 51: 867-871.
Kleinhenz J.M., Kleinhenz D.J., You S. et al. Am J Physiol Heart Circ Physiol 2009; 297: H1647-H1654.
Chang L., Villacorta L., Zhanget J. et al. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation 2009; 119: 2161-2169.
Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
Stuhlinger M.C., Abbasi F., Chu J.W. et al. Relationship between insulin resistance and an endogenous nitiric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
Liu Z. The renin-angiotensin system and insulin resistance. Curr Diab Rep 2007; 7 (1): 34-42.
Memisoglu A., Hu F.B., Hankinson S.E. et al. http://www.ncbi.nlm.nih.gov/pubmed?term=Manson%20JE%5BAuthor%5D&cauthor=true&cauthor.... Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003; 12: 2923-2929.
Huang C.L., Kuo E. Mechanisms of Disease: WNK-ing at the mechanism of salt-sensitive hypertension. Nature Clin Pract Nephrol 2007; 3 (11): 623-630.
Reaven G.M., Hoffman B.B. A role for insulin in the aetiology and course of hypertension? Lancet 1987; 2 (8556): 435-437.
Steinberg H.O., Brechtel G., Johnson A. et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Investigat 1994; 94 (3): 1172-1179.
Robitaille J., Despres J.P., Perusse L., Vohl M.C. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 2003; 63: 109-116.
Schlaich M.P., Lambert E., Kaye D.M. et al. Sympathetic nervous augmentation in essential hypertension: role of nerve firing, norepinephrine reuptake and angiotensin neuromodulation. Hypertension 2004; 43: 169-175.
Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376: 1903-1909.
Festa A., D'Agostino Jr R., Howard G. еt al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
Aizawa-Abe M., Ogawa Y., Masuzaki H. еt al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2010; 105: 1243-1252.
Bataineh A., Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68: S14-S19.
Sesso H.D., Buring J.E., Rifai N. еt al. C-reactive protein and the risk of developing ypertension. JAMA 2003; 290: 2945-2951.
Li J., Doerffel Y., Hocher C.B. Inflammation in the genesis of hypertension and its complications-the role of angiotensin II. Nephrol Dialys Transplantat 2007; 22 (11): 3107-3109.
Christopher B.J., Gregory Y.H. Is Hypertension an Inflammatory Process? Cur Pharmaceut Design 2006; 12: 1623-1635.
Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
Pauletto P., Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 2006; 21: 850-853.
Endemann D.H., Schiffrin E.L. Endothelial Dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
Licastro F., Candore G., Domenico Lio еt al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005; 2: 8-17.
Lonn E.M., Gerstein H.C., Sheridan P. et al. Diabetes reduction assessment with ramipril and rosiglitazone medication. J Am Coll Cardiol 2009; 53: 2028-2035.
Ricote M., Valledor A.F., Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 230-239.
Clarke D.L., Patel H.J., Mitchell .A. Regulation of the release of colony-stimulating factors from human airway smooth muscle cells by prostaglandin E2. Br J Pharmacol 2001; 133: 40-45.
Al-Shali K.Z., House A.A., Hanley J.G. еt al. Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis. Stroke 2004; 35 (9): 2036-2040.
Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: Interactions with glucocorticoids and beta 2-agonists. Biol Chem 2004; 324: 47-50.

Авторы

М.С. РАСИН

Украинская медицинская стоматологическая академия, Полтава

________________________________________________

M.S. RASIN

Ukrainian Academy of Medicine and Dentistry, Poltava

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.